Pfizer: FDA approves new indication for Lorbrena
(CercleFinance.com) - Pfizer announces that the US FDA has approved its application to expand the indication for Lorbrena (lorlatinib) and prescribe it as first-line treatment for metastatic ALK-positive metastatic non-small cell lung cancer (NSCLC).
Benjamin Solomon, Department of Medical Oncology, Peter MacCallum Cancer Centre, said, "This approval is meaningful for my patients because we now have a highly effective treatment option that can delay the progression of a typically aggressive disease".
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Benjamin Solomon, Department of Medical Oncology, Peter MacCallum Cancer Centre, said, "This approval is meaningful for my patients because we now have a highly effective treatment option that can delay the progression of a typically aggressive disease".
Copyright (c) 2021 CercleFinance.com. All rights reserved.